Why AbbVie Shares Are Trading Lower Today

AbbVie Inc ABBV has reported Q1 adjusted EPS of $2.46, down 22.2% Y/Y, in line with the consensus.

Overall sales decreased 9.7% Y/Y (down 8.3% on an operational basis) to $12.23 billion, beating the consensus of $12.17 billion.

The immunology portfolio generated $5.59 billion in sales, down 9% (-7.8% on an operational basis). Humira sales decreased 25.2% to $3.54 billion. In Q4, Humira sales increased 4.6% to $5.56 billion.

Skyrizi sales reached $1.36 billion (+44.7% Y/Y), and Rinvoq jumped 47.5% to $686 million, lower than $1.58 billion and $770 million in Q4, respectively.

Related: AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says.

Hematologic oncology portfolio sales were $1.42 billion, down 14% (-12.9% on an operational basis). Imbruvica sales decreased 25.2% to $878 million. Venclexta revenues were up 13.7% to $538 million.

Sales from the neuroscience portfolio reached $1.69 billion, +13.9%. Aesthetics portfolio sales decreased 5.4% to $1.3 billion, with $659 million in Botox sales for cosmetic uses.

Guidance: AbbVie has revised FY23 adjusted EPS guidance of $10.72 - $11.12 compared to previous guidance of $10.62 - $11.02 and the consensus of $10.94.

Price Action: ABBV shares are down 7.27% at $150.04 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!